Patent ID: 11911513
Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTD
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 3:
4. The method of claim 3, wherein the tooth matching component and the drug-loaded component are connected on respective sides; or the drug-loaded component has a reticular structure or a nonreticular structure, and the drug-loaded component has a cross section in the shape of a circular, elliptical, polygonal, or special-shaped closed ring or open ring structure;
or, the drug fastened module is one or more reservoirs; or, the retention enabling module can fit to any one or more teeth in the oral cavity; or, the retention enabling module is customized to fit and wrap, clamp or insert teeth;
or, the drug-loaded component comprises at least one ring body and at least one retainer, or the drug-loaded component is constituted by at least one retainer; wherein the ring body has an opening for insertion of a medicinal tablet, and the retainer has a structure for limiting the medicinal tablet in the drug-loaded component; or the tooth is maxillary tooth or mandibular tooth;
or, the opening faces the molars in a horizontal direction formed by the molars and the incisors, and is used to enable the medicinal tablet to be inserted from the molars toward the incisors in the horizontal direction; or the opening is provided in a direction perpendicular to the horizontal direction such that the medicinal tablet is inserted down from the above in the direction perpendicular to the horizontal direction; or the opening faces the buccal side in a direction perpendicular to the horizontal direction such that the medicinal tablet is inserted from the buccal side to the lingual side in the direction perpendicular to the horizontal direction; or, the tooth is the mandibular molar, mandibular second molar or its anterior and posterior molar;
or, the reservoir has a basket structure; or, the shape of the cross section of the reservoir is polygon, circular closed-loop or circular open-loop, or a combination thereof;
or, at least one end of the reservoir is connected with a cover, so that the extended release platform is maintained in the reservoir; or, at least one end of the reservoir is connected with a strip, so that the extended release platform is maintained in the reservoir;
or, the retention enabling module is customized to fit and wrap, clamp or insert the entire maxillary teeth or the entire mandibular permanent teeth;
or, the retention enabling module is customized to wrap, clamp or insert the mandibular permanent teeth;
or, the retention enabling module is customized to wrap the mandibular molar;
or, the retention enabling module is customized to wrap, clamp or insert the second mandibular molar and its adjacent parts of the first molar and the second bicuspid;
or, the active pharmaceutical ingredient comprises levodopa or carbidopa; or, the excipient is one or more of filler, osmotic agent, hydrophilic polymer, binding agent, lubricant, preservative, flavoring agent, acidifying agent and antioxidant; or, the excipient is one or more of filler, osmotic agent, hydrophilic polymer, binding agent, lubricant and preservative; or, the excipients are filler, osmotic agent, hydrophilic polymer, binding agent, lubricant and preservative;
or, when the pharmaceutically active ingredient comprises levodopa, the weight percentage of the levodopa is 20-70%; when the active ingredient comprises carbidopa, the weight percentage of carbidopa is 0-20% but not 0%; wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, when the pharmaceutically active ingredient comprises levodopa, the weight percentage of the levodopa is 30-50%; when the active ingredient comprises carbidopa, the weight percentage of carbidopa is 1-10%; wherein the weight percentage is the weight percentage of each component of the drug-containing layer;
or, in the extended release platform, the tablet core of the pharmaceutical composition further comprises an osmotic push layer, and the osmotic push layer comprises a hydrophilic polymer, an osmotic agent and a binding agent; or, the osmotic push layer comprises a hydrophilic polymer, an osmotic agent, a binding agent, and a lubricant; or, the osmotic push layer comprises a hydrophilic polymer, an osmotic agent, a binding agent, a lubricant and a colorant;
or, wherein in the extended release platform, the coating membrane of the pharmaceutical composition is further overcoated with a drug-containing immediate release overcoat;
the drug-containing immediate release overcoat comprises an active pharmaceutical ingredient and an excipient, the active pharmaceutical ingredient comprises levodopa or carbidopa, and the excipient is one or more of hydroxypropyl cellulose, aspartame and mint flavor; wherein, when the active pharmaceutical ingredient is levodopa, the weight percentage of the levodopa is 0-75% but not 0%, or 23.78-75%;
or, when the active pharmaceutical ingredient is carbidopa, the weight percentage of carbidopa is 0-93% but not 0%, or 26.85-93%;
or, when the excipient of the overcoat comprises hydroxypropyl cellulose, the weight percentage of the hydroxypropyl cellulose is 2-20%, or 10%;
or, when the excipient of the overcoat comprises aspartame, the weight percentage of the aspartame is 0-5%, or 0.9-5%;
or, when the excipient of the overcoat comprises mint flavor, the weight percentage of the mint flavor is 0-5%, or 0.1%; wherein the weight percentage is the weight percentage of each component of the overcoat;
or, wherein in the extended release platform, the weight of the coating membrane is not less than 2.0% of the weight of the tablet core; the coating membrane has one or more orifices, and the diameter of orifice is 0.5 mm-1.0 mm, or 0.5 mm, 0.75 mm and 1.0 mm;
or, the weight of the coating membrane is 2.0-15.0% of the weight of the tablet core; or, the weight of the coating membrane is 4.0-8.0% of the weight of the tablet core.